Menu Search
Equities

Integrated Biopharma Inc

INBP:QXR

Integrated Biopharma Inc

Actions
  • Price (USD)0.32
  • Today's Change0.01 / 3.23%
  • Shares traded300.00
  • 1 Year change+18.52%
  • Beta0.5798
Data delayed at least 15 minutes, as of Nov 13 2024 15:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Integrated Biopharma Inc had relatively flat revenues (50.67m to 50.32m), though the company grew net income from a loss of 34.00k to a gain of 112.00k. A reduction in the selling, general and administrative costs as a percentage of sales from 7.78% to 7.22% was a component in the net income growth despite flat revenues.
Gross margin7.72%
Net profit margin0.22%
Operating margin0.50%
Return on assets0.43%
Return on equity0.59%
Return on investment0.55%
More ▼

Cash flow in USDView more

In 2024, Integrated Biopharma Inc increased its cash reserves by 27.43%, or 361.00k. The company earned 943.00k from its operations for a Cash Flow Margin of 1.87%. In addition the company used 553.00k on investing activities and also paid 29.00k in financing cash flows.
Cash flow per share0.0143
Price/Cash flow per share21.06
Book value per share0.6391
Tangible book value per share0.6391
More ▼

Balance sheet in USDView more

Integrated Biopharma Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.04%.
Current ratio2.92
Quick ratio1.08
Total debt/total equity0.0004
Total debt/total capital0.0004
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 790.57%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-42.26
EPS (TTM) vs
TTM 1 year ago		331.58
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.